<mods:mods version="3.0" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-0.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>Management of Diabetic Neuropathy</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Raymond</mods:namePart><mods:namePart type="family">Azman Ali</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Diabetes mellitus is the commonest cause of neuropathy worldwide. Diabetic neuropathy (DN) develops in about 4-10% of diabetic patients after 5 years and in 15% after 20 years.Four main mechanisms have been postulated to underlie the pathogenesis of DN. Diabetic neuropathy can be divided into symmetrical and asymmetrical neuropathies. Diabetic Autonomic Neuropathy (DAN) parallels the severity of DSN, and affects primarily the cardiovascular, gastrointestinal, genitourinary and integumentary systems. The cornerstone of treatment of diabetic neuropathy is optimization of glycaemic control. Future treatments for diabetic neuropathy should address the underlying pathogenesis.</mods:abstract><mods:classification authority="lcc">R Medicine, Dentistry, Pharmacy, Nursing</mods:classification><mods:originInfo><mods:dateIssued encoding="iso8061">2003-07</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>School of Medical Sciences, Kubang Kerian, Universiti Sains Malaysia</mods:publisher></mods:originInfo><mods:genre>Journal</mods:genre></mods:mods>